Eli Lilly and BigHat Biosciences collaborate on AI-driven antibody discovery
Eli Lilly partnered with BigHat Biosciences to co-develop next-generation therapeutic antibodies using AI technology. BigHat's Milliner platform leverages machine learning and synthetic biology high-speed wet labs to optimize key antibody attributes for accelerated biologics development.